Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2%

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s share price traded up 6.2% on Monday . The company traded as high as $16.98 and last traded at $16.98. 42,326 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 145,459 shares. The stock had previously closed at $15.99.

Wall Street Analysts Forecast Growth

TYRA has been the subject of several analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Wednesday. Wedbush reiterated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Tyra Biosciences in a report on Wednesday.

Tyra Biosciences Price Performance

The company has a market cap of $891.60 million, a PE ratio of -10.10 and a beta of 1.01. The stock’s 50-day moving average is $17.62 and its 200 day moving average is $16.57.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.11. On average, analysts expect that Tyra Biosciences, Inc. will post -1.71 EPS for the current year.

Insider Transactions at Tyra Biosciences

In other news, COO Daniel Bensen sold 3,502 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $20.00, for a total value of $70,040.00. Following the sale, the chief operating officer now directly owns 427,981 shares of the company’s stock, valued at approximately $8,559,620. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 15.40% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. boosted its position in shares of Tyra Biosciences by 1,244.2% in the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after purchasing an additional 1,916 shares during the period. Exchange Traded Concepts LLC raised its holdings in shares of Tyra Biosciences by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock valued at $132,000 after buying an additional 2,417 shares during the last quarter. AJOVista LLC purchased a new position in shares of Tyra Biosciences during the fourth quarter worth about $59,000. Wellington Management Group LLP increased its position in Tyra Biosciences by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after acquiring an additional 8,324 shares during the period. Finally, Fishman Jay A Ltd. MI purchased a new position in shares of Tyra Biosciences in the 1st quarter valued at approximately $246,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.